- Home
- IGIC vs REPL Comparison
IGIC vs REPL Comparison
Compare IGIC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGIC
- REPL
- Stock Information
- Founded
- IGIC 2001
- REPL 2015
- Country
- IGIC Jordan
- REPL United States
- Employees
- IGIC N/A
- REPL N/A
- Industry
- IGIC Property-Casualty Insurers
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- IGIC Finance
- REPL Health Care
- Exchange
- IGIC Nasdaq
- REPL Nasdaq
- Market Cap
- IGIC 1.0B
- REPL 851.0M
- IPO Year
- IGIC N/A
- REPL 2018
- Fundamental
- Price
- IGIC $26.48
- REPL $8.62
- Analyst Decision
- IGIC Buy
- REPL Strong Buy
- Analyst Count
- IGIC 2
- REPL 6
- Target Price
- IGIC $31.50
- REPL $20.00
- AVG Volume (30 Days)
- IGIC 81.9K
- REPL 727.0K
- Earning Date
- IGIC 05-06-2025
- REPL 05-15-2025
- Dividend Yield
- IGIC 3.60%
- REPL N/A
- EPS Growth
- IGIC 16.99
- REPL N/A
- EPS
- IGIC 2.98
- REPL N/A
- Revenue
- IGIC $539,000,000.00
- REPL N/A
- Revenue This Year
- IGIC $34.93
- REPL $31.16
- Revenue Next Year
- IGIC $6.00
- REPL N/A
- P/E Ratio
- IGIC $8.88
- REPL N/A
- Revenue Growth
- IGIC 7.95
- REPL N/A
- 52 Week Low
- IGIC $12.83
- REPL $4.92
- 52 Week High
- IGIC $27.76
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- IGIC 54.56
- REPL 24.38
- Support Level
- IGIC $25.17
- REPL $10.17
- Resistance Level
- IGIC $26.98
- REPL $10.78
- Average True Range (ATR)
- IGIC 0.92
- REPL 0.65
- MACD
- IGIC 0.04
- REPL -0.24
- Stochastic Oscillator
- IGIC 55.77
- REPL 12.39
About IGIC International General Insurance Holdings Ltd.
International General Insurance Holdings Ltd is an international specialist commercial insurer and a reinsurer, underwriting a diverse portfolio of specialty lines. The company operates in a portfolio of Energy, Property, Construction, Engineering, Ports and terminals, Financial Institutions, General Aviation, Professional Indemnity, Casualty, Directors and Officers, Political Violence, Forestry, and Treaty Reinsurance. Its operating segment includes Specialty Longtail; Specialty Short tail and Reinsurance.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.